Press Releases

Press Releases

November 5, 2018
TEGSEDI TM (inotersen) Approved in United States , European Union & Canada          $320 million to fund the company through key milestones Conference Call Webcast Monday, November 5 , 4:30 p.m. ET at www.akceatx.com BOSTON , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
November 2, 2018
Community focuses on elevating awareness of the burden of FCS and impact on daily living BOSTON , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics , Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , today recognizes the inaugural Familial Chylomicronemia Syndrome (FCS) Awareness
October 22, 2018
Webcast scheduled for Monday, November 5 th at 4:30 p.m. Eastern Time BOSTON , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Monday, November 5 th at 4:30 p.m.
October 8, 2018
Dr. Damien McDevitt replaces Dr. Stanley Crooke on Akcea Board of Directors The change enhances focus on global approval and commercialization of TEGSEDI™ (inotersen) BOSTON , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
October 5, 2018
Express Scripts’ Accredo® selected as specialty pharmacy for its expertise in providing timely access and support services for patients living with rare diseases BOSTON , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
October 5, 2018
TEGSEDI provides powerful knockdown of TTR protein, delivering significant and sustained benefits in neuropathy and quality of life Hereditary Transthyretin (hATTR) Amyloidosis Infographic AKCEA CONNECT™ Infographic TEGSEDI™ (inotersen) Product Shot Ionis Pharmaceuticals Logo TEGSEDITM(inotersen)
October 4, 2018
First and only treatment of its kind for Canadians with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy – a rare and inherited disease OTTAWA and BOSTON and CARLSBAD, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics Inc.
September 24, 2018
Study demonstrates significant Lp(a) reduction, favorable safety and tolerability profile Largest and longest study of Ionis’ LICA technology Data to be presented as a late-breaking clinical trial presentation at AHA on November 10 in Chicago CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept.
August 29, 2018

CAMBRIDGE, Mass. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , today announced that management will present a company overview at the Wells Fargo Healthcare Conference at 4:10 p.m.

August 27, 2018

CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today announced that they received a Complete Response Letter (CRL) from the Division of